Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer

被引：0
作者：
Akinsola, Olutiwa A. [1 ]
Talwar, Ruchika [1 ]
Baskin, Avi [1 ]
Luckenbaugh, Amy N. [1 ]
Awamlh, Bashir Al Hussein Al [2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA
[2] Weill Cornell Med, Dept Urol, 525 East 68th St,Starr 900, New York, NY 10065 USA
来源：
TRANSLATIONAL ANDROLOGY AND UROLOGY | 2024年 / 13卷 / 06期
关键词：
Bacillus Calmette-Gu & eacute; rin (BCG); high-risknon-muscle invasive bladder cancer (high-risk NMIBC); immunotherapy; atezolizumab; SINGLE-ARM; OPEN-LABEL; BCG; PEMBROLIZUMAB; MULTICENTER; CG0070;
D O I：
10.21037/tau-23-630
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
Treatment options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unfit or unwilling to undergo radical cystectomy remain limited (1). Due to the lack of treatment options for this group of patients, especially in light of the continued global bacillus Calmette-Guérin (BCG) shortage (2), both the American Urological Association and the Food and Drug Administration (FDA) deemed single-arm phase 2 or 3 trials to be sufficient for approval of alternative treatment options into patient care. As of December 2022, intravesical valrubicin, intravenous pembrolizumab, and intravesical nadofaragene firadenovec remain the only FDA-approved treatments for BCG-unresponsive high-risk NMIBC. © Translational Andrology and Urology. All rights reserved.
引用
收藏
页码：1061 / 1063
页数：3
相关论文
共 14 条
  • [1] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
  • [2] Al Hussein Al Awamlh B, 2023, ASCO Daily NewsJanuary 18,
  • [3] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    Balar, Arjun, V
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence E. M.
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Li, Haojie
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    de Wit, Ronald
    [J]. LANCET ONCOLOGY, 2021, 22 (07) : 919 - 930
  • [4] Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin- unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605
    Black, Peter C.
    Tangen, Catherine M.
    Singh, Parminder
    McConkey, David J.
    Lucia, M. Scott
    Lowrance, William T.
    Koshkin, Vadim S.
    Stratton, Kelly L.
    Bivalacqua, Trinity J.
    Kassouf, Wassim
    Porten, Sima P.
    Bangs, Rick
    Plets, Melissa
    Thompson, Ian M.
    Lerner, Seth P.
    [J]. EUROPEAN UROLOGY, 2023, 84 (06) : 536 - 544
  • [5] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, Joseph E.
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Svatek, Robert S.
    Mashni, Joseph, Jr.
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence I.
    Woods, Michael E.
    Brown, Gordon
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Krupski, Tracey
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Keegan, Kirk A.
    Andriole, Gerald L., Jr.
    Sankin, Alexander I.
    Boyd, Alan
    O'Donnell, Michael A.
    Sawutz, David
    Philipson, Richard
    Coll, Ruth
    Narayan, Vikram M.
    Treasure, F. Peter
    Yla-Herttuala, Seppo
    Parker, Nigel R.
    Dinney, Colin P. N.
    [J]. LANCET ONCOLOGY, 2021, 22 (01) : 107 - 117
  • [6] Castellano D, 2023, J CLIN ONCOL, V41
  • [7] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
    De Santis, Maria
    Abdrashitov, Ramil
    Hegele, Axel
    Kolb, Margaret
    Parker, Suzanne
    Redorta, Juan Palou
    Nishiyama, Hiroyuki
    Xiao, Feng
    Gupta, Ashok Kumar
    Shore, Neal D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] FDA CDER & Mccrayk, 2018, BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry
  • [9] Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines
    Flaig, Thomas W.
    Spiess, Philippe E.
    Abern, Michael
    Agarwal, Neeraj
    Bangs, Rick
    Boorjian, Stephen A.
    Buyyounouski, Mark K.
    Chan, Kevin
    Chang, Sam
    Friedlander, Terence
    Greenberg, Richard E.
    Guru, Khurshid A.
    Herr, Harry W.
    Hoffman-Censits, Jean
    Kishan, Amar
    Kundu, Shilajit
    Lele, Subodh M.
    Mamtani, Ronac
    Margulis, Vitaly
    Mian, Omar Y.
    Michalski, Jeff
    Montgomery, Jeffrey S.
    Nandagopal, Lakshminarayanan
    Pagliaro, Lance C.
    Parikh, Mamta
    Patterson, Anthony
    Plimack, Elizabeth R.
    Pohar, Kamal S.
    Preston, Mark A.
    Richards, Kyle
    Sexton, Wade J.
    Siefker-Radtke, Arlene O.
    Tollefson, Matthew
    Tward, Jonathan
    Wright, Jonathan L.
    Dwyer, Mary A.
    Cassara, Carly J.
    Gurski, Lisa A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (08): : 866 - 878
  • [10] Hahn NM, 2020, J CLIN ONCOL, V38
12